94 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
, 2023, there were 75,370,977 common shares and 2,173,081 pre-funded warrants outstanding.
Research and development expenses were $41.1 million … , respectively. The increase in research and development expenses for the year was primarily attributable to expenses related to Xenon's enrollment
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
partnered products and product candidates are dependent upon the research, development and marketing efforts of our collaborators.
S-3
Our reliance … to incur significant research and development and other expenses related to our clinical development and ongoing operations. As a result, we
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
of our partnered products and product candidates are dependent upon the research, development and marketing efforts of our collaborators.
S-3
Our … product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical development
8-K
EX-99.1
gzyrz9xf3
8 Nov 23
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
5iqic0yje b4714
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
g8ewv1wh
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
d93ja 4wqk4h77mc
8 Nov 22
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
424B5
3w2jsi2y
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
35w d039ydu
22 Jun 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
rfz9wgcy
10 May 22
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
424B5
5t4tgpfxlrl jz82
1 Mar 22
Prospectus supplement for primary offering
5:12pm